STA inks license and commercialisation agreement with PharmaMar for APLIDIN (plitidepsin)

by The Medical News • 2015/08/20 • 0 Comments

Australian biopharmaceutical company Specialised Therapeutics Australia has struck an exclusive license and commercialisation agreement with European pharmaceutical partner company PharmaMar to market and distribute the novel oncology drug APLIDIN (plitidepsin) in Australia and New Zealand.

← Stem cells derived from amniotic membrane can benefit retinal diseases when transplanted

Publication Exclusive: Corneal cross-linking may have application in infective keratitis →

Post navigation